glp-1 direct A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders that results are subtle and vary among individuals Supergut: Glp 1 Prebiotic Daily

Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study

GLP-1RAs vs metformin (ancillary analysis) Several studies have shown that metformin may correct components of the metabolic syndrome [23]

Inflammation is part of the bodys natural response to injury and infection

These findings might be partly explained by short follow-up, different doses of l-carnitine, and the inclusion of low-quality trials without randomization and blinding [14, 15]

Critically it provided the first evidence of the 'posttranslational processing of a polypeptide precursor into the mature functional form of the hormone by specialized proteolytic enzymes'

The shape, depth, and width of the microneedle determine the delivery rate [41,42,43]